📊 EARNINGS SEASON ANALYZER — MARCH 27, 2026

Earnings Report Card: How 4 Major Companies Compare to Titan Biotech’s Quality Benchmarks

By Manish Goel | multibaggershares.com

This week, several Indian companies announced their quarterly results. As a value investor, I always ask one simple question: “Does this company match the quality benchmark set by Titan Biotech?” Today, we compare BSE Ltd, Biocon, Bank of India, and Indian Bank against our gold-standard benchmark — and the results are revealing.

🏆 The Gold Standard: Titan Biotech (Q3 FY26)

This is what a quality small-cap multibagger looks like. Let’s see how others compare…

1. BSE Ltd — Grade: A-

The Good: BSE Ltd delivered record-breaking Q3 FY26 results with revenue surging 62% YoY to ₹1,244 crore and net profit soaring 173% to ₹596.59 crore. Operating EBITDA tripled to ₹732 crore with a spectacular 59% margin. The exchange processed 21.7 crore mutual fund transactions — a 21% increase — commanding 87.4% market share in mutual fund processing.

The Reality Check: While BSE Ltd has a higher profit growth rate of 173% compared to Titan Biotech’s 94%, Titan Biotech delivers the complete package of growth + quality + small market cap. BSE Ltd already has a market cap of ₹30,000+ crore — the massive multibagger returns are already done. Titan Biotech’s small size means far more upside potential for patient investors. BSE is also heavily dependent on market cycles — when markets crash, BSE’s revenue drops dramatically. Titan Biotech sells essential biochemical products with consistent demand.

2. Biocon — Grade: B

The Good: Biocon reported Q3 FY26 revenue of ₹4,173 crore (up 9% YoY) with a dramatic 475% surge in net profit to ₹144 crore. The biosimilars segment grew 9% with EBITDA improving 44% YoY, and the generics business delivered strong 24% YoY growth.

The Reality Check: While Biocon’s 475% profit growth looks impressive on paper, the base was extremely low (coming from near-losses). The ROCE is a dismal 4.36% compared to Titan Biotech’s 16.9%. Biocon carries significant debt from its $5.5 billion Biocon Biologics integration. A 4.36% ROCE means the company is barely generating returns above its cost of capital. Titan Biotech is almost debt-free and generates nearly 4x the return on capital — that’s the difference between real quality and headline-grabbing numbers.

3. Bank of India — Grade: B-

The Good: Bank of India reported interest income of ₹19,052 crore (up 4% YoY) with net profit of ₹2,814 crore (up 6.7% YoY). The bank’s gross NPA improved, indicating strengthening asset quality.

The Reality Check: A 6.7% profit growth from a public sector bank is average at best. Banks are inherently leveraged businesses — they borrow to lend. You cannot compare their balance sheet quality to a debt-free manufacturing company like Titan Biotech. While Bank of India manages ₹7.9 lakh crore in deposits, Titan Biotech’s 94% profit growth with near-zero debt demonstrates far superior capital efficiency and wealth-creation potential for retail investors. PSU banks also face constant government interference and have historically destroyed shareholder value through repeated dilutions.

4. Indian Bank — Grade: B

The Good: Indian Bank delivered net profit of ₹3,061 crore (up 7% YoY) with operating profit crossing the ₹5,000 crore milestone. Net interest income grew 7.5% to ₹6,896 crore, and asset quality improved with gross NPA declining to 2.23%. Deposits grew an impressive 12.6% YoY.

The Reality Check: Indian Bank is performing well for a PSU bank — but 7% profit growth is what you get from a fixed deposit, not from a quality stock. Titan Biotech’s 94% profit growth is literally 13x faster. Indian Bank’s business model depends entirely on interest rate cycles controlled by RBI. Titan Biotech manufactures biochemicals with growing global demand — its growth is driven by business fundamentals, not monetary policy. For long-term wealth creation, the difference is night and day.

🎯 Key Takeaway

This week’s earnings confirm what we’ve been teaching: quality companies like Titan Biotech consistently outperform on the metrics that matter most — profit growth, ROCE, and balance sheet strength.

BSE Ltd had strong results, but it’s already a ₹30,000 Cr company. Biocon’s profit growth looks impressive but it’s built on a weak ROCE and heavy debt. The PSU banks grew profits in single digits. Meanwhile, Titan Biotech delivered 94% profit growth with 16.9% ROCE, near-zero debt, and a 331% stock price return in just one year.

The lesson? Don’t chase headlines. Chase quality. That’s value investing.

⚠️ Important Warning: Say NO to F&O Gambling

SEBI data consistently shows that over 90% of retail traders lose money in Futures & Options. Don’t destroy your wealth chasing quick gains in derivatives. Instead, invest in quality companies for the long term — that’s how real wealth is built.

The companies profiled above have taken decades to build their businesses. Respect the process. Be a patient investor, not a gambler.

📚 Learn Value Investing — Free Course by Manish Goel

Master the art of finding quality stocks like Titan Biotech. Watch the complete “Value Investing with Manish Goel” course playlist on YouTube.

▶ Watch Free Course Playlist

About Manish Goel: Value investor and founder of multibaggershares.com, on a mission to educate 200 million Indian stock market investors about quality investing. Manish identified Titan Biotech at ~₹55, which has since delivered 200%+ returns — a testament to the power of fundamental analysis and patience. His stock picks have been read by India’s top investors including Mohnish Pabrai’s team.